ADMA BIOLOGICS, INC. - 10-Q Filing
ADMA Biologics reports increased cash position of $124.6 million for the quarter ended September 30, 2026.
Tickers: $ADMA
Read the full article at SEC EDGAR
Part of the story Vera Therapeutics Reports Q3 2026 Results Following TRUTAKNA Commercial Launch (9 articles)